Indication
Liver Insufficiency
Aliases
Hepatic Insufficiency
14 clinical trials
15 products
Clinical trial
Pharmacokinetics of Imlunestrant in Participants With Hepatic ImpairmentStatus: Completed, Estimated PCD: 2024-02-28
Product
ImlunestrantClinical trial
An Open-label, Nonrandomized, Single-dose, Parallel-group, Safety, Tolerance, and Pharmacokinetic Study of LOXO-305 Administered to Fasted Hepatically Impaired Male and Female Subjects and Fasted Matched-control Healthy SubjectsStatus: Completed, Estimated PCD: 2021-12-30
Product
PirtobrutinibProduct
BI 425809Clinical trial
Pharmacokinetics, Safety and Tolerability of BI 425809 (Iclepertin) Following Oral Administration in Male and Female Participants With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) Compared With Matched Male and Female Participants With Normal Hepatic Function (an Open-label, Non-randomised, Single-dose, Parallel, Individualmatched Design Trial)Status: Completed, Estimated PCD: 2023-12-11
Clinical trial
A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy ParticipantsStatus: Recruiting, Estimated PCD: 2024-10-01
Product
LY3437943Product
LY3502970Clinical trial
A Phase 1, Multicenter, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic ImpairmentStatus: Recruiting, Estimated PCD: 2024-07-01
Product
JaktinibClinical trial
Study To Evaluate The Pharmacokinetics Of Jaktinib Hydrochloride Tablets In Subjects With Hepatic Impairment And Normal Hepatic FunctionStatus: Completed, Estimated PCD: 2022-09-19
Product
Jaktinib HydrochlorideClinical trial
A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Onureg®) in Subjects With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Adult Subjects With Myeloid MalignanciesStatus: Recruiting, Estimated PCD: 2025-06-01
Product
OnuregClinical trial
Pharmacokinetics, Safety and Tolerability of BI 1015550 Following Oral Administration in Male and Female Participants With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) Compared With Matched Male and Female Participants With Normal Hepatic Function (an Open-label, Non-randomised, Single-dose, Parallel, Individual-matched Design Trial)Status: Completed, Estimated PCD: 2023-09-13
Product
BI 1015550Product
UlonivirineClinical trial
An Open-Label, Single-Dose Clinical Study to Evaluate Pharmacokinetics of MK-8507 in Participants With Mild or Moderate Hepatic Impairment.Status: Not yet recruiting, Estimated PCD: 2025-04-03
Product
TirzepatideProduct
nevirapineClinical trial
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic ImpairmentStatus: Completed, Estimated PCD: 2020-09-22
Clinical trial
A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic FunctionStatus: , Estimated PCD: 2006-06-01
Product
CeftobiproleClinical trial
Retrospective Chart Review to Evaluate the Safety Profile of Ceftobiprole in Patients With Impaired Hepatic or Renal Function or ImmunosuppressionStatus: Completed, Estimated PCD: 2023-06-09
Clinical trial
Phase I Clinical Study to Evaluate the Pharmacokinetics, Pharmacokinetics, and Safety of Intravenous Administration of Methoxyethyl Etomidate Hydrochloride for Injection in Subjects With Mild, Moderate, and Normal Hepatic Dysfunction.Status: Recruiting, Estimated PCD: 2024-03-30
Product
ET-26Clinical trial
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic FunctionStatus: Not yet recruiting, Estimated PCD: 2025-01-28
Product
Simufilam